New Delhi: Drug maker Glenmark Pharmaceuticals today said it has entered the phase II clinical trials for its new drug molecule aimed at treating ulcerative colitis. The company`s subsidiary Glenmark Pharmaceuticals SA will conduct trials at multiple clinical sites in North America and Europe to investigate the efficacy and safety of the new molecule GBR 500, Glenmark Pharmaceuticals said in a statement. It is expected that the trial will include nearly eighty four patients with moderate to severe ulcerative colitis (UC), it added. Commenting on the development Glenmark Pharmaceuticals Chief Scientific Officer Michael Buschle said: "Despite treatment advances in recent years, UC remains a debilitating condition for many individuals, and represents an area of substantial unmet medical need."
Gut microbes help body absorb more fat from food
Apollo Hospitals enters African market